{"nctId":"NCT00778921","briefTitle":"Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone","startDateStruct":{"date":"2008-10"},"conditions":["Hypertension"],"count":847,"armGroups":[{"label":"Amlodipine 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Amlodipine 10 mg"]},{"label":"Aliskiren/Amlodipine 150/10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Amlodipine 10 mg","Drug: Aliskiren 150"]},{"label":"Aliskiren/Amlodipine 300/10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Amlodipine 10 mg","Drug: Amlodipine 300"]}],"interventions":[{"name":"Amlodipine 10 mg","otherNames":[]},{"name":"Aliskiren 150","otherNames":[]},{"name":"Amlodipine 300","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP ≥ 95 mmHg and \\< 110 mmHg at Visits 1 and 2\n* Patients who have been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP ≥ 90 mmHg and \\< 110 mmHg at Visit 2\n* All patients must have a msDBP ≥ 90 mmHg and \\< 110 mmHg at Visit 5 (randomization)\n\nExclusion Criteria:\n\n* Severe hypertension\n* Pregnant or nursing (lactating) women\n* Pre-menopausal women not taking accepted form of birth control\n* Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1\n* History of cardiovascular conditions\n* Uncontrolled Type 1 or Type 2 diabetes mellitus\n* Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with similar chemical structures\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.99","spread":"0.462"},{"groupId":"OG001","value":"-8.95","spread":"0.460"},{"groupId":"OG002","value":"-7.23","spread":"0.459"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.42","spread":"0.684"},{"groupId":"OG001","value":"-11.01","spread":"0.681"},{"groupId":"OG002","value":"-8.20","spread":"0.680"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Any Adverse Event and/or Serious Adverse Event in the Double-blind Period by Treatment Group","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"92","spread":null}]}]}]},{"type":"SECONDARY","title":"Biomarker Assessment at Visit 2 (Single Blind Run in), Visit 5 (Randomization), and Visit 9 (EOS)","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":279},"commonTop":["Oedema peripheral","Nasopharyngitis"]}}}